Abstract
Stereotactic ablative radiotherapy (sabr) is a relatively new technique for the curative-intent treatment of patients with inoperable early-stage non-small-cell lung cancer (nsclc). Previous studies have demonstrated a prognostic value for positron emission tomography-computed tomography (pet/ct) parameters, including maximal standardized uptake value (suvmax), metabolic tumour volume (mtv), and total lesion glycolysis (tlg) in lung cancer patients. We aimed to determine which pet/ct parameter is most prognostic of local control (lc) and overall survival (os) in patients treated with sabr for nsclc. We conducted a retrospective review of patients treated with sabr for stage I inoperable nsclc at BC Cancer between 2009 and 2013. The Akaike information criterion was used to compare the prognostic value of the various pet/ct parameters. The study included 134 patients with a median age of 76 years. Median tumour diameter was 2.2 cm, gross tumour volume was 8.1 mL, suvmax was 7.9, mtv was 2.4 mL, and tlg was 10.9 suv·mL. The 2-year lc was 92%, and os was 66%. On univariate and multivariate analysis, imaging variables including tumour size, gross tumour volume, suvmax, mtv, and tlg were all associated with worse lc. Tumour size was not associated with significantly worse os, but other imaging variables were. The pet/ct parameter most prognostic of lc was mtv. Compared with suvmax, tlg and mtv were more prognostic of os. In patients with early-stage nsclc treated with sabr, mtv appears to be prognostic of lc and os.
Highlights
Stereotactic ablative radiotherapy is a relatively new technique for the curative-intent treatment of patients with inoperable early-stage non-small-cell lung cancer
In patients with early-stage nsclc treated with sabr, mtv appears to be prognostic of lc and os
Surgical resection is the current standard of care for patients with early-stage node-negative non-small-cell lung cancer[2], but stereotactic ablative radiotherapy, called stereotactic body radiotherapy, has become the standard treatment for patients with early nsclc who are unwilling or unable to undergo a curative resection[3]
Summary
Stereotactic ablative radiotherapy (sabr) is a relatively new technique for the curative-intent treatment of patients with inoperable early-stage non-small-cell lung cancer (nsclc). Surgical resection is the current standard of care for patients with early-stage node-negative non-small-cell lung cancer (nsclc)[2], but stereotactic ablative radiotherapy (sabr), called stereotactic body radiotherapy, has become the standard treatment for patients with early nsclc who are unwilling or unable to undergo a curative resection[3]. For this group of patients with early-stage disease, who often have substantial comorbidities, relatively few clinical prognostic factors have been described. Previous studies have focused mainly on the maximal standardized uptake value (suvmax), with most (but not all) studies showing that a greater suvmax is associated with worse outcomes[6,7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
